• Citer

Gene expression signatures can predict the efficacy of anthracyclines in HER2-negative and HER2-positive breast cancer (BC) patients: The results of the TOP trial and their validation in the BIG1-00 trial.

par Desmedt, Christine ;Haibe-Kains, Benjamin ;de Azambuja, Evandro ;Larsimont, Denis ;Delaloge, Suzette;Duhem, Caroline;Di Leo, Angelo ;D'Hondt, Veronique ;Piccart-Gebhart, Martine ;Sotiriou, Christos
Référence IMPAKT Breast Cancer Conference(May 7-9, 2009: Brussels, Belgium), Annals of Oncology, Vol. vol 20 Suppl 2, page (ii45)
Publication Publié, 2009-05

Abstract de conférence

• Détails
• Contenu

Titre:	Gene expression signatures can predict the efficacy of anthracyclines in HER2-negative and HER2-positive breast cancer (BC) patients: The results of the TOP trial and their validation in the BIG1-00 trial.
Auteur:	Desmedt, Christine; Haibe-Kains, Benjamin; de Azambuja, Evandro; Larsimont, Denis; Delaloge, Suzette; Duhem, Caroline; Di Leo, Angelo; D'Hondt, Veronique; Piccart-Gebhart, Martine; Sotiriou, Christos
Informations sur la publication:	IMPAKT Breast Cancer Conference(May 7-9, 2009: Brussels, Belgium), Annals of Oncology, Vol. vol 20 Suppl 2, page (ii45)
Statut de publication:	Publié, 2009-05
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Langue:	Anglais